Aurinia Pharmaceuticals (AUPH) Expected to Post Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is anticipated to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $0.19 per share and revenue of $80.4480 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.07. The firm had revenue of $77.71 million for the quarter, compared to analyst estimates of $76.98 million. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%. On average, analysts expect Aurinia Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aurinia Pharmaceuticals Stock Down 0.8%

AUPH opened at $15.22 on Tuesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.55 and a quick ratio of 5.01. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 7.01 and a beta of 1.41. The business has a 50-day moving average of $15.99 and a two-hundred day moving average of $15.36. Aurinia Pharmaceuticals has a 12 month low of $8.80 and a 12 month high of $19.25.

Insider Activity at Aurinia Pharmaceuticals

In other news, CEO Kevin Tang acquired 343,620 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were bought at an average cost of $15.28 per share, for a total transaction of $5,250,513.60. Following the acquisition, the chief executive officer directly owned 12,838,101 shares in the company, valued at $196,166,183.28. This trade represents a 2.75% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders bought 814,606 shares of company stock valued at $12,455,129. Company insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC lifted its position in Aurinia Pharmaceuticals by 864.5% during the fourth quarter. Corient Private Wealth LLC now owns 275,472 shares of the biotechnology company’s stock valued at $4,394,000 after buying an additional 246,912 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth $406,000. Uniplan Investment Counsel Inc. raised its stake in shares of Aurinia Pharmaceuticals by 31.3% in the 4th quarter. Uniplan Investment Counsel Inc. now owns 120,202 shares of the biotechnology company’s stock valued at $1,917,000 after acquiring an additional 28,645 shares during the period. Voloridge Investment Management LLC raised its stake in shares of Aurinia Pharmaceuticals by 44.3% in the 4th quarter. Voloridge Investment Management LLC now owns 739,444 shares of the biotechnology company’s stock valued at $11,794,000 after acquiring an additional 226,875 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of Aurinia Pharmaceuticals by 4.7% during the 4th quarter. Wellington Management Group LLP now owns 53,721 shares of the biotechnology company’s stock valued at $857,000 after acquiring an additional 2,421 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Zacks Research cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings lowered shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $17.25.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.